Viewing Opinion | StockChase

Spdr S&P Biotech Etf (XBI-N) opinion on 2017-10-10

Last Price Recorded: 81.8200 on 2017-12-15

ON STOCKCHASE SINCE Jun 2016

E.T.F.'s
E.T.F.'s
TOP PICK

Cameron Hurst
Spdr S&P Biotech Etf was $87.630 at time of opinion
Owned : Yes

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

OPTIMISTIC

All opinions for XBI-N (3)

1 BUY
1 COMMENT
1 TOP PICK
View All

More experts covering XBI-N

SAVE
Add XBI-N to Watch List

All opinions for XBI-N (3)

1 BUY
1 COMMENT
1 TOP PICK
View All

More experts covering XBI-N

SAVE
Add XBI-N to Watch List

Last 60 Days Opinions

No opinions for COMPANY TICKER in the last 60 days

No Comments.


You must be logged in to comment.

Successfully Saved Company